. Expression of TfR1. Flow cytometry analysis of membrane TfR1 expression. HER2-positive (i.e. BT474 and SKBR3) and Estrogen Receptor positive (i. e. MCF-7) breast cell lines have been tested assessing their membrane TfR1 expression. Cells immunodecorated with the anti-mouse secondary antibody conjugated with AlexaFluor 488 were used to set the gate on viable cells, on singlets and the region of positivity.
. Expression of TfR1. Flow cytometry analysis of membrane TfR1 expression. HER2-positive (i.e. BT474 and SKBR3) and Estrogen Receptor positive (i. e. MCF-7) breast cell lines have been tested assessing their membrane TfR1 expression. Cells immunodecorated with the anti-mouse secondary antibody conjugated with AlexaFluor 488 were used to set the gate on viable cells, on singlets and the region of positivity. Statistical significance vs. untreated cells, *P < 0.05; **P < 0.005; ***P < 0.0005 (Student's t-test). Figure S6 . Safety of copper used for encapsulation. MCF-7 cells treated with 1.5, 0.15 and 0.015 μM of copper for 72 h have been used to demonstrate the safety of copper used for Eve nanoformulation. Viability was assessed by measuring the conversion of MTS into formazan. Reported values are the mean of six replicates ± s.e., normalized on cell proliferation of untreated cells, respectively. Statistical significance vs. untreated cells, *P < 0.05; **P < 0.005; ***P < 0.0005 (Student's t-test). Figure S7 . Cell death assay of SKBR3 and MDA-MB 231 cells treated with increasing concentration of nanoformulated Eve or Eve for 72h. Reported values are the mean of three replicates ± s.e., normalized on cell proliferation of untreated cells, respectively. Statistical significance of HEve vs. free drug; *P < 0.005; ***P < 0.0001 (Student's t-test).
